ATE253633T1 - Cystic fibrosis gen - Google Patents

Cystic fibrosis gen

Info

Publication number
ATE253633T1
ATE253633T1 AT90912428T AT90912428T ATE253633T1 AT E253633 T1 ATE253633 T1 AT E253633T1 AT 90912428 T AT90912428 T AT 90912428T AT 90912428 T AT90912428 T AT 90912428T AT E253633 T1 ATE253633 T1 AT E253633T1
Authority
AT
Austria
Prior art keywords
sequence
amino acid
dna
dna sequences
acid residue
Prior art date
Application number
AT90912428T
Other languages
English (en)
Inventor
Lap-Chee Tsui
John R Riordan
Francis S Collins
Johanna M Rommens
Michael C Iannuzzi
Bat-Sheva Kerem
Mitchell L Drumm
Manual Buchwald
Original Assignee
Hsc Res Dev Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Corp, Univ Michigan filed Critical Hsc Res Dev Corp
Application granted granted Critical
Publication of ATE253633T1 publication Critical patent/ATE253633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT90912428T 1989-08-22 1990-08-20 Cystic fibrosis gen ATE253633T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39689489A 1989-08-22 1989-08-22
US39994589A 1989-08-24 1989-08-24
US40160989A 1989-08-31 1989-08-31
PCT/CA1990/000267 WO1991002796A1 (en) 1989-08-22 1990-08-20 Cystic fibrosis gene

Publications (1)

Publication Number Publication Date
ATE253633T1 true ATE253633T1 (de) 2003-11-15

Family

ID=27410233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90912428T ATE253633T1 (de) 1989-08-22 1990-08-20 Cystic fibrosis gen

Country Status (9)

Country Link
EP (2) EP1418183A1 (de)
JP (3) JPH05500306A (de)
AT (1) ATE253633T1 (de)
CA (1) CA2066204C (de)
DE (1) DE69034115T2 (de)
DK (1) DK0489058T3 (de)
ES (1) ES2210224T3 (de)
IE (2) IE903024A1 (de)
WO (1) WO1991002796A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063913A (en) * 1989-08-22 2000-05-16 Hsc Research And Development Limited Partnership Stable heterologous propagation CFTR protein variant cDNA
US5543399A (en) * 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
US6984487B1 (en) 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
DE69132616T2 (de) * 1990-01-12 2002-02-21 Hsc Research Development Corp., Toronto Introns und exons des gens für cystische fibrose sowie mutationen an mehreren stellen des gens
US5674898A (en) * 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
US5981714A (en) * 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
US7118911B1 (en) 1990-03-05 2006-10-10 Genzyme Corporation DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5939536A (en) * 1990-03-05 1999-08-17 Genzyme Corporation Methods for purifying cystic fibrosis transmembrane conductance regulation
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
ATE132742T1 (de) * 1991-08-16 1996-01-15 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
US6013638A (en) * 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993012240A1 (en) * 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9217885D0 (en) * 1992-08-21 1992-10-07 Medical Res Council Mutant mice
FR2700011B1 (fr) * 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
EP0642795B1 (de) * 1993-02-24 1999-05-12 Gunze Limited Arznei gegen cystische fibrosen
AU7644494A (en) * 1993-09-08 1995-03-27 Genzyme Corporation A method for purifying a membrane-associated protein
US5688677A (en) * 1993-10-13 1997-11-18 Genzyme Corporation Deoxyribonucleic acids containing inactivated hormone responsive elements
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US5858671A (en) 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6258533B1 (en) 1996-11-01 2001-07-10 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
AU736506B2 (en) * 1997-12-03 2001-07-26 Genentech Inc. Polypeptides and nucleic acids encoding the same
EP1191101B1 (de) * 1997-12-11 2004-06-09 Genentech, Inc. PRO241 Polypeptide und dafür kodierende Nukleinsäuren
AU2001265728A1 (en) 2000-06-08 2001-12-17 Lawson Research Institute Diagnosis and classification of disease and disability using low frequency magnetic field designed pulses (cnps)
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
EP1655608A1 (de) * 2004-11-04 2006-05-10 Inserm CFTR als Komponente vom Autophagie-Signalweg, deren Verwendung in autophagischen Krankheiten, und Bestimmung von Mukoviszidose als autophagische Krankheit
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
JP2013521829A (ja) * 2010-03-22 2013-06-13 エソテリックス ジェネティック ラボラトリーズ， エルエルシー 嚢胞性線維症に関連する突然変異
PL2861733T3 (pl) 2012-05-30 2021-04-19 Rowan University Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego
MX2021008832A (es) * 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709652D0 (en) * 1987-04-23 1987-05-28 Williamson R Diagnosis of cystic fibrosis
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator

Also Published As

Publication number Publication date
CA2066204C (en) 2009-03-31
DE69034115D1 (en) 2003-12-11
JP2002355088A (ja) 2002-12-10
WO1991002796A1 (en) 1991-03-07
IE20040698A1 (en) 2004-12-01
JP2004208694A (ja) 2004-07-29
EP1418183A1 (de) 2004-05-12
ES2210224T3 (es) 2004-07-01
EP0489058A1 (de) 1992-06-10
EP0489058B1 (de) 2003-11-05
JPH05500306A (ja) 1993-01-28
IE903024A1 (en) 1991-02-27
CA2066204A1 (en) 1991-02-23
AU6161690A (en) 1991-04-03
DE69034115T2 (de) 2004-07-15
DK0489058T3 (da) 2004-03-22
AU647408B2 (en) 1994-03-24

Similar Documents

Publication Publication Date Title
DE69034115D1 (en) Cystic fibrosis gen
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
AU659330B2 (en) RNA catalyst for cleaving specific RNA sequences
EP2014770A3 (de) WNT-1-induziertes sekretiertes Polypeptid WISP-2
HK20292A (en) Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
ATE216427T1 (de) Verfahren zur herstellung von polypeptidabkömmlingen
CA2192940A1 (en) Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections
NO179412C (no) Hybrid DNA-molekyl som koder for fibronektinbindende protein, mikroorganismer inneholdende slike DNA-molekyler samt fremgangsmåte ved fremstilling av slikt protein
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
DK346385D0 (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
DE69739524D1 (de) Dp-75 kodierende dna und verfahren zu ihrer verwendung
WO1993017031A3 (en) Nucleic acids encoding dystrophin-associated proteins
ATE455562T1 (de) Endothelzellspezifität zeigende promotoren und verfahren zu deren verwendung
DE3587205D1 (de) Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle.
DE3572843D1 (en) Site-specific proteolysis by renin
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
DK551786A (da) Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed
DK1129191T3 (da) Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme
WO1999049045A3 (de) Rekombinantes hauptallergen des pollens von artemisia vulgaris (beifuss)
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen
WO1999019491A3 (en) Human dnax interleukin-40 (dil-40)
TH43867A (th) ลำดับกรดนิวคลีอิคและกรดอะมิโนที่เกี่ยวข้องกับ Helicobacter pyroli และองค์ประกอบวัคซีนของมัน
ATE409225T1 (de) Durch wnt-1 induzierbare gene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0489058

Country of ref document: EP

EELA Cancelled due to lapse of time